Rosenberg et al. found that the alteration of DDR pathway-related genes was significantly associated with a higher tumor mutation burden and predicted the optimized anti-PD-1/PD-L1 immunotherapy efficiency (Arora et al., 2019) (Teo et al., 2018). Here, PDCD1 is linked to neoplasm.